Your browser doesn't support javascript.
Anti-fibrotic agents could be the game-changer for post-COVID-19 pulmonary fibrosis treatment
European Journal of Biological Research ; 12(1):1-10, 2022.
Article in English | CAB Abstracts | ID: covidwho-2275410
ABSTRACT
More than 220 countries and territories are globally affected by the recent pandemic COVID-19 which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There is possibility of third wave of this pandemic as per epidemiological and public health experts. Besides that post-COVID-19 complications are alarming matter to look upon. Post-COVID-19 complications include several symptoms like as persistent fever;cough;fatigue;headache;attention disorder;dyspnea;anosmia;ageusia;chest pain discomfort;various respiratory illness;acute respiratory distress syndrome (ARDS) etc., and here the things to worry about is the development of pulmonary fibrosis after COVID-19. In some COVID-19 patients, hyper-inflammation in the form of 'cytokine storm' along with dysregulated immune response, alveolar epithelial tissue injury and wound repair collectively cause this secondary pulmonary fibrosis. Therefore, using anti-fibrotic agents e.g. pirfenidone, nintedanib and other natural compounds could be meaningful in these circumstances although their efficacy in treating COVID-19 is subject to more detailed laboratory research works. In this review article, we have discussed the progression of pulmonary fibrosis development which is triggered by COVID-19;probable solutions with anti-fibrotic agents including anti-fibrotic drugs, some well-known natural compounds, combined anti-fibrotic therapies;and the current challenges of this field.
Keywords
Prion; Viral; Bacterial and Fungal Pathogens of Humans [VV210], Non-communicable Human Diseases and Injuries [VV600], Biological Resources (General) [PP700], coronavirus disease 2019, human diseases, respiratory diseases, pandemics, viral diseases, lungs, fibrosis, medical treatment, complications, symptoms, public health, epidemiology, fever, cough, fatigue, headaches, attention deficit hyperactivity disorder, dyspnoea, anosmia, inflammation, cytokines, immune response, epithelium, wounds, healing, reviews, drug therapy, geographical distribution, spatial distribution, Severe acute respiratory syndrome coronavirus 2, man, France, Russia, Brazil, India, Turkey, UK, Argentina, USA, Severe acute respiratory syndrome-related coronavirus, Betacoronavirus, Coronavirinae, Coronaviridae, Nidovirales, positive-sense ssRNA Viruses, ssRNA Viruses, RNA Viruses, viruses, Homo, Hominidae, primates, mammals, vertebrates, Chordata, animals, eukaryotes, European Union Countries, high income countries, Mediterranean Region, OECD Countries, very high Human Development Index countries, Western Europe, Europe, APEC countries, upper-middle income countries, Community of Portuguese Language Countries, high Human Development Index countries, Latin America, America, South America, Commonwealth of Nations, lower-middle income countries, medium Human Development Index countries, South Asia, Asia, West Asia, British Isles, North America, chest pain, pirfenidone, nintedanib, antifibrotic agents, SARS-CoV-2, lung diseases, viral infections, pyrexia, tiredness, dyspnea, immunity reactions, immunological reactions, chemotherapy, Russian Federation, Britain, United Kingdom, United States of America

Full text: Available Collection: Databases of international organizations Database: CAB Abstracts Topics: Long Covid Language: English Journal: European Journal of Biological Research Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: CAB Abstracts Topics: Long Covid Language: English Journal: European Journal of Biological Research Year: 2022 Document Type: Article